window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : August 10, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

IND-enabling studies

  • Central Nervous System,Drug Discovery & Development,Research & Development

    AstronauTx exercises Saniona option for neurological disease candidate

    AstronauTx has exercised its option to acquire worldwide rights to [...]

    August 10, 2026
  • Advanced Therapies,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Atsena selects clinical candidate for Stargardt disease gene therapy

    ATSN-401, Atsena Therapeutics’ investigational gene therapy for Stargardt disease, has [...]

    July 10, 2026
  • Advanced Therapies,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    OrganaBio to manufacture RxMP haemostatic therapy RMP-402

    OrganaBio has entered a manufacturing partnership with RxMP Therapeutics to [...]

    June 11, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza expands DNA-to-IND offering to accelerate biologics development timelines

    Lonza has expanded its integrated DNA-to-IND biologics development offering, introducing [...]

    June 8, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AC Immune amends Lilly collaboration on Tau small molecules for Alzheimer’s disease

    AC Immune has amended its collaboration agreement with Eli Lilly [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    etherna intratumoral mRNA/LNP platform advances toward IND studies in non-melanoma skin cancer

    etherna, a biotech company specialising in mRNA and lipid nanoparticle [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Nucleome Therapeutics appoints Michelle Morrow as chief scientific officer

    Nucleome Therapeutics has appointed Michelle Morrow as chief scientific officer, [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Nucleome Therapeutics nominates first preclinical development candidate for inflammatory diseases

    Nucleome Therapeutics has nominated its first preclinical development candidate, marking [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    DEBRA Research and Nonsense Therapeutics launch ReadOn Therapeutics to target epidermolysis bullosa

    DEBRA Research gGmbH, a global non-profit dedicated to advancing research [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug
    Categories: Central Nervous System, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Norstella launches agentic AI platform for biopharma decision-making
    Categories: Biotech & Pharma Business, Digital & Data, Drug Discovery & Development
  • AI model cuts radiopharmaceutical dose mapping to seconds in prostate cancer study
    Categories: Digital & Data, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top